Madrid-based life sciences specialist Cross Road Biotech Inversiones Biotecnológicas (CRB) has acquired a 50% stake in biotech start-up Mecwins for around €4m.
Consortium of investors supporting the funding round includes existing and new backers
Vehicle is larger than its predecessor, Xenon Private Equity VI, a €184m fund closed in July 2014
GP intends to boost the company's organic growth and further strengthen its market position
Acquisition of the family-owned company adds to the GP's industrial portfolio